Topical Avastin for Treatment of Corneal Neovascularization

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts Eye and Ear Infirmary
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Male or female, at least 18 years of age

• Clinical stable corneal neovascularization (as defined above)

• Ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits.

• All female patients of childbearing potential will be excluded. A female is considered to be of childbearing potential unless she is postmenopausal and without menses for 12 months or without a uterus and/or both ovaries.

Exclusion Criteria:

• Current or recent (≤ 1 month) systemic corticosteroid therapy or periocular corticosteroid injections to the study eye

• Current or recent (≤ 3 months) intravitreal drug injection to the study eye; recent (≤ 1 month) change in dose and frequency of topical steroids and/or non-steroidal anti-inflammatory agents

• Uncontrolled hypertension defined as systolic blood pressure of ≥ 150 mmHg or diastolic blood pressure of ≥ 90 mmHg; history of a thromboembolic event, including myocardial infarction or cerebral vascular accident

• Patients age 75 or older; history of renal abnormalities

• Recent (≤ 3 months ) or planned surgery

• History of coagulation abnormalities, including end stage liver disease or current anticoagulation medication other than aspirin (warfarin, heparin, enoxaparin, or similar anticoagulant agent)

• All female patients of childbearing potential (a female is considered to be of childbearing potential unless she is postmenopausal and without menses for 12 months or without a uterus and/or both ovaries)

• Any condition (including language barrier) that precludes patient's ability to comply with study requirements including completion of study